Europe
Summit Therapeutics plc announced that it presented results from the Phase 2 clinical trial of ridinilazole in C. difficile infection (‘CDI’) detailing improvements in patient quality of life following antibiotic treatment for CDI.
Araris Biotech AG announced the appointment of Dr. Rakesh Dixit, Dr. John Lambert and Dr. L. Nathan Tumey as members of its Scientific Advisory Board.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Life science and pharma companies strengthen their leadership teams with this week’s appointments.
In 2017, a lawsuit was filed alleging that Eli Lilly and Bayer, as well as other companies, attempted to use the free nursing services as a way to boost sales of diabetes drugs, such as Humalog and Humulin, as well as other drugs.
In a Phase III trial, Cosentyx showed a significant and clinically meaningful reduction in disease activity for patients versus placebo.
Industry’s most widely used platform for screening data analysis accelerates Eisai’s novel drug discovery
Heidelberg Pharma AG announced that it has adjusted its guidance for the current fiscal year published in March 2019.
CELLINK began collaborating with Prellis Biologics to develop the Holograph X bioprinter in 2018, and the technology was recently recognized enabling innovative capabilities for the pharmaceutical industry.
G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regulatory Affairs and Quality Assurance, has announced the opening of new offices in Basel, Switzerland.
PRESS RELEASES